Lexicon Pharmaceuticals Inc. plans to deploy its sales force Friday and have its first approved product, Xermelo (telotristat ethyl, previously LX-1032/LX-1606), available Monday for dispensing through its specialty pharmacies following the oral drug's approval by the FDA to treat carcinoid syndrome diarrhea in patients living with metastatic neuroendocrine tumors, or mNETs.